Skip to main content
Equibles
AXSM logo

AXSM · Axsome Therapeutics, Inc. · Earnings Call Transcripts & Audio

Track AXSM — free

Use AXSM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AXSM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$184.39 -1.75 (-0.94%)
Russell 1000 member Rebalance outlook locked
Market Cap
$9.75B
Shares
52.38M
Volume · Sep 30 1.03M Avg daily vol (3M) 703.8K

Axsome Therapeutics, Inc. Earnings Call Transcripts

Quarterly earnings calls for Axsome Therapeutics, Inc. (AXSM), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $16.85M −$44.82M '22 Q3 22-11-07 · $94.58M −$11.22M '23 Q1 23-05-08 ▲429.5% $46.70M −$67.17M '23 Q2 23-08-07 ▲243.1% $57.79M −$62.20M '23 Q3 23-11-06 · $71.53M −$98.65M '23 Q4 24-02-20 ▼20.7% $75.00M −$68.36M '24 Q1 24-05-06 ▲86.7% $87.17M −$79.34M '24 Q2 24-08-05 ▲81.3% $104.76M −$64.60M '24 Q3 24-11-12 ▲66% $118.77M −$74.91M '24 Q4 25-02-18 ▲62% $121.46M −$59.41M '25 Q1 25-05-05 ▲72.1% $150.04M −$47.97M '25 Q2 25-08-04 ▲63.2% $170.99M −$47.23M '25 Q3 25-11-03 ▲65% $196.00M −$28.56M '25 Q4 26-02-23 ▲57.4% $191.20M −$64.54M '26 Q1 26-05-04 LATEST ▲45.5% $218.38M −$51.31M '26 Q2 26-08-10
Conference
Investor event
2026-09-16
Axsome Therapeutics, Inc. (AXSM) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-14
Axsome Therapeutics, Inc. (AXSM) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-09
Axsome Therapeutics, Inc. (AXSM) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-10
Axsome Therapeutics, Inc. (AXSM) Q2 2026 Earnings Call Transcript
Confident tone Alzheimer's disease agitation launch Sales force expansion Gross-to-net and financials
Revenue
$218.38M
▲ 45.5% YoY
Diluted EPS
$-0.99
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-08
Axsome Therapeutics, Inc. (AXSM) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-04
Axsome Therapeutics, Inc. (AXSM) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-03
Axsome Therapeutics, Inc. (AXSM) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-04
Axsome Therapeutics, Inc. (AXSM) Q1 2026 Earnings Call Transcript
Confident tone Pipeline advancement and NDA submissions Avelity FDA approval in Alzheimer's disease agitation (ADA) Sunosi and Symbravo commercial performance
Revenue
$191.20M
▲ 57.4% YoY
Diluted EPS
$-1.26
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-23
Axsome Therapeutics, Inc. (AXSM) Q4 2025 Earnings Call Transcript
Confident tone Auvelity commercial growth Cymbravo launch Solriamfetol label expansion pipeline
Revenue
$196.00M*
▲ 65% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-03
Axsome Therapeutics, Inc. (AXSM) Q3 2025 Earnings Call Transcript
Confident tone AXS-12 narcolepsy NDA AUVELITY commercial performance AXS-05 Alzheimer's disease agitation
Revenue
$170.99M
▲ 63.2% YoY
Diluted EPS
$-0.94
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-04
Axsome Therapeutics, Inc. (AXSM) Q2 2025 Earnings Call Transcript
Confident tone Commercial growth / Auvelity and Sunosi SYMBRAVO launch Solriamfetol expansion indications
Revenue
$150.04M
▲ 72.1% YoY
Diluted EPS
$-0.97
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-05
Axsome Therapeutics, Inc. (AXSM) Q1 2025 Earnings Call Transcript
Confident tone Revenue growth & commercial performance Solriamfetol lifecycle expansion (ADHD, MDD, BED, SWD) Symbravo launch & EMERGE data
Revenue
$121.46M
▲ 62% YoY
Diluted EPS
$-1.22
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-18
Axsome Therapeutics, Inc. (AXSM) Q4 2024 Earnings Call Transcript
Confident tone Late-stage pipeline and NDAs Auvelity commercial growth Solriamfetol label expansion
Revenue
$118.77M*
▲ 66% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Axsome Therapeutics, Inc. (AXSM) Q3 2024 Earnings Call Transcript
Confident tone Auvelity commercial momentum Solriamfetol (AXS-12 / Sunosi) life-cycle expansion AXS-05 Alzheimer's disease agitation Phase 3 readouts
Revenue
$104.76M
▲ 81.3% YoY
Diluted EPS
$-1.34
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-05
Axsome Therapeutics, Inc. (AXSM) Q2 2024 Earnings Call Transcript
Confident tone Auvelity commercial momentum Solriamfetol pipeline expansion Sunosi performance
Revenue
$87.17M
▲ 86.7% YoY
Diluted EPS
$-1.67
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-06
Axsome Therapeutics, Inc. (AXSM) Q1 2024 Earnings Call Transcript
Confident tone Alzheimer's disease agitation program Auvelity commercial performance Solriamfetol pipeline expansion
Revenue
$75.00M
▼ 20.7% YoY
Diluted EPS
$-1.44
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-20
Axsome Therapeutics, Inc. (AXSM) Q4 2023 Earnings Call Transcript
Confident tone Sunosi revenue and out-licensing AXS-05 in Alzheimer's disease agitation (ADVANCE-2) AXS-12 in narcolepsy (SYMPHONY trial)
Revenue
$71.53M*
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-06
Axsome Therapeutics, Inc. (AXSM) Q3 2023 Earnings Call Transcript
Revenue
$57.79M
▲ 243.1% YoY
Diluted EPS
$-1.32
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-07
Axsome Therapeutics, Inc. (AXSM) Q2 2023 Earnings Call Transcript
Revenue
$46.70M
▲ 429.5% YoY
Diluted EPS
$-1.54
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-08
Axsome Therapeutics, Inc. (AXSM) Q1 2023 Earnings Call Transcript
Revenue
$94.58M
Diluted EPS
$-0.26
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-27
Axsome Therapeutics, Inc. (AXSM) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-07
Axsome Therapeutics, Inc. (AXSM) Q3 2022 Earnings Call Transcript
Revenue
$16.85M
Diluted EPS
$-1.07
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-23
Axsome Therapeutics, Inc. (AXSM) Q2 2022 Earnings Call Transcript
Revenue
$8.82M
Diluted EPS
$-1.06
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-02
Axsome Therapeutics, Inc. (AXSM) Q1 2022 Earnings Call Transcript
Diluted EPS
$-1.06
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-01
Axsome Therapeutics, Inc. (AXSM) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-08
Axsome Therapeutics, Inc. (AXSM) Q3 2021 Earnings Call Transcript
Revenue
$
Diluted EPS
$-0.93
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
Axsome Therapeutics, Inc. (AXSM) Q2 2021 Earnings Call Transcript
Revenue
$
Diluted EPS
$-0.86
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-10
Axsome Therapeutics, Inc. (AXSM) Q1 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-01
Axsome Therapeutics, Inc. (AXSM) Q4 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Axsome Therapeutics, Inc. (AXSM) Q3 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-10
Axsome Therapeutics, Inc. (AXSM) Q2 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-08
Axsome Therapeutics, Inc. (AXSM) Q1 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-12
Axsome Therapeutics, Inc. (AXSM) Q4 2019 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–33 of 33 earnings calls
Key facts CIK 1579428 CUSIP 05464T104 13F (30d) 9 filings 9 filers Visit website Investor relations